GSK
2 years ago ⋅ English ⋅ 6 min read
Newsroom
GSK launches £6m programme to boost STEM career progression for young people from under-represented groups in the UK

For media and investors only- GSK to invest £6m in STEM equity-focused initiatives in the UK over ten years to tackle barriers to entry in STEM careers (Science, Technology, Engin... Read More
GSK
2 years ago ⋅ English ⋅ 6 min read
Newsroom
ViiV Healthcare receives approval from China’s National Medical Products Administration (NMPA) for Vocabria (cabotegravir) used in combination with Rekambys (rilpivirine), the first and only complete long-acting HIV-1 injectable treatment

For media and investors only- The marketing authorisation for rilpivirine long-acting injection was received on the 18 October 2023- The complete long-acting regimen enables people livi... Read More
GSK
2 years ago ⋅ English ⋅ 5 min read
Newsroom
New data for Arexvy, GSK’s RSV vaccine, show potential to help protect adults aged 50 to 59 at increased risk for RSV disease

For media and investors only- Preliminary results from phase III trial show primary endpoints met, with non-inferior immune responses observed in adults aged 50-59 compared to adults ag... Read More
GSK
2 years ago ⋅ English ⋅ 2 min read
Newsroom
GSK enters exclusive license agreement with Hansoh for HS-20089

For media and investors only- Hansoh’s HS-20089 complements GSK’s portfolio of gynaecologic cancer therapiesGSK plc (LSE/NYSE: GSK) and Hansoh Pharma (HKEX: 03692), a Chines... Read More
GSK
2 years ago ⋅ English ⋅ 8 min read
Newsroom
ViiV Healthcare to present 23 abstracts from innovative HIV treatment and prevention portfolio at EACS 2023

For media and investors only- Key data to be presented include long-term and real-world data from ViiV Healthcare’s portfolio of medicines, including long-acting and 2-drug regime... Read More
GSK
2 years ago ⋅ English ⋅ 8 min read
Newsroom
GSK highlights new data in non-small cell lung cancer and endometrial cancer at the European Society for Medical Oncology (ESMO) Congress 2023, reinforcing potential of Jemperli (dostarlimab) as a backbone immuno-oncology therapy

For media and investors only- Late-breaking data from head-to-head PERLA trial shows favourable numerical trend in overall survival (OS) results for Jemperli (dostarlimab) plus chemothe... Read More